Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
2-PYRROLIDONE
ID: ALA276849
Max Phase: Preclinical
Molecular Formula: C4H7NO
Molecular Weight: 85.11
Molecule Type: Small molecule
Associated Items:
ID: ALA276849
Max Phase: Preclinical
Molecular Formula: C4H7NO
Molecular Weight: 85.11
Molecule Type: Small molecule
Associated Items:
Synonyms (1): Pyrrolidin-2-one
Synonyms from Alternative Forms(1):
Canonical SMILES: O=C1CCCN1
Standard InChI: InChI=1S/C4H7NO/c6-4-2-1-3-5-4/h1-3H2,(H,5,6)
Standard InChI Key: HNJBEVLQSNELDL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 85.11 | Molecular Weight (Monoisotopic): 85.0528 | AlogP: -0.10 | #Rotatable Bonds: 0 |
Polar Surface Area: 29.10 | Molecular Species: NEUTRAL | HBA: 1 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: -0.58 | CX LogD: -0.58 |
Aromatic Rings: 0 | Heavy Atoms: 6 | QED Weighted: 0.44 | Np Likeness Score: 0.05 |
1. Li C, Schwartz EL, Mella SL, Rittmann LS, Sartorelli AC.. (1981) Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones., 24 (9): [PMID:6945436] [10.1021/jm00141a016] |
2. Altomare C, Cellamare S, Carotti A, Casini G, Ferappi M, Gavuzzo E, Mazza F, Carrupt PT, Gaillard P, Testa B.. (1995) X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore., 38 (1): [PMID:7837228] [10.1021/jm00001a022] |
3. Reddy PA, Hsiang BC, Latifi TN, Hill MW, Woodward KE, Rothman SM, Ferrendelli JA, Covey DF.. (1996) 3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents., 39 (9): [PMID:8627613] [10.1021/jm9600196] |
4. Sykes NO, Macdonald SJ, Page MI.. (2002) Acylating agents as enzyme inhibitors and understanding their reactivity for drug design., 45 (13): [PMID:12061887] [10.1021/jm0111245] |
5. Imming P, Klar B, Dix D.. (2000) Hydrolytic stability versus ring size in lactams: implications for the development of lactam antibiotics and other serine protease inhibitors., 43 (22): [PMID:11063627] [10.1021/jm000921k] |
6. Kim YC, Zhao LX, Kim TH, Je SM, Kim EK, Choi H, Chae WG, Park M, Choi J, Jahng Y, Lee ES.. (2000) Design and synthesis of anticonvulsive agents as gamma-vinyl GABA-based potential dual acting prodrugs and their biological activities., 10 (7): [PMID:10762036] [10.1016/s0960-894x(00)00064-0] |
7. Sasaki H, Mori Y, Nakamura J, Shibasaki J.. (1991) Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives., 34 (2): [PMID:1847429] [10.1021/jm00106a025] |
8. Caboni P, Sarais G, Aissani N, Tocco G, Sasanelli N, Liori B, Carta A, Angioni A.. (2012) Nematicidal activity of 2-thiophenecarboxaldehyde and methylisothiocyanate from caper (Capparis spinosa) against Meloidogyne incognita., 60 (30): [PMID:22769561] [10.1021/jf302075w] |
9. PubChem BioAssay data set, |
10. PubChem BioAssay data set, |
11. (2018) Modulators of Prostate-Specific G-Protein Receptor (PSGR/OR51E2) and Methods of Using Same, |
Source(3):